Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-05-26
2010-11-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361100
Reexamination Certificate
active
07838546
ABSTRACT:
In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided.Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.
REFERENCES:
patent: 2004/0044258 (2004-03-01), Shoda et al.
patent: 2004/0235817 (2004-11-01), Brands et al.
patent: 2005/0032787 (2005-02-01), Giannessi et al.
patent: 2006/0276525 (2006-12-01), Adin et al.
patent: 1653032 (2005-08-01), None
patent: 0 470 832 (1992-02-01), None
patent: 0 473 308 (1992-03-01), None
patent: 1 024 130 (2000-08-01), None
patent: 1 323 701 (2003-07-01), None
patent: 1 477 472 (2004-11-01), None
patent: WO 03/070686 (2003-08-01), None
patent: WO 2005/016862 (2005-02-01), None
Additional Information Regarding Properties of 3-[3-amino-4(indian-2-yloxy)-5-1-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid Made Under Different Conditions, Dec. 11, 2008.
Brittain et al., Polymorphism in Pharmaceutical Solids, vol. 95, p. 228-229, 1999.
Byrn et al., Solid-State Chemistry of Drugs, 1999, SSCI, Inc., Second Edition, pp. 62-63.
Chawla et al., Challenges in Polymorphism of Pharmaceuticals, CRIPS, vol. 5, No. 1, Jan.-Mar. 2004, pp. 9-12.
Newman et al., Solid-State analysis of the active pharmeceutical ingredient in drug products, DDT, vol. 8, No. 19, Oct. 2003, pp. 898-905.
EP 07 79 0690, European Search Report, Aug. 11, 2010, 7 pages.
CA 2,659,471; Office Action, Jul. 5, 2010, pp. 1-3.
Mino R. Caira, “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, vol. 198, Jan. 1, 1998, pp. 163-208, XP001156954.
Asahi Kasei Pharma Corporation
Bianchi Kristin
Birch & Stewart Kolasch & Birch, LLP
Saeed Kamal A
LandOfFree
Crystal of substituted phenylalkanoic acid ester and process... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal of substituted phenylalkanoic acid ester and process..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal of substituted phenylalkanoic acid ester and process... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153885